Link Ideas for Life

What we offer

Research & Training services in the field of Drug Discovery and Nutraceuticals.

Pharma-Biotech

• Elucidation of chemical action/reaction mechanisms
• Multi-target drug optimization
• Repurposing of proprietary compounds

Agri-food Nutraceuticals

• Identification of natural bioactive components
• Poly-pharmacological profiling
• Valorization of typical natural products

Expert Training

• Enhancing the multi-target /
poly-pharmacology knowledge
• Advanced courses for professional experts
• Linking complementary skills

Last News

Release of the Full and Short FAD – Mu.Ta.Lig COST Action CA15135 Video produced by Net4Science

Net4Science is proud to announce the release of the Full and Short versions of the Final Action Dissemination (FAD) – Mu.Ta.Lig COST Action CA15135 Video, which are now available at the www.mutalig.eu.

The Mu.Ta.Lig COST Action started on April 2016 with the aim to join several highly-qualified research teams to improve the multi-target drug discovery. It has been active for four years and more than 30 European countries have been involved in this project. Net4Science started to strongly collaborate with the Mu.Ta.Lig COST Action for scientific and dissemination projects. Indeed, most of the Net4Science publications were made in collaboration with this COST Action. Additionally, another effective project carried out by the Net4Science spinoff was the recent release of three Chemotheca video tutorials, created with the aim to support the use of the Chemotheca tool.

Last October it was planned the idea to complete the dissemination program through the collection of all the documentation related to the meetings, scientific publications, mobility and interviews, which gave birth to the Final Action Dissemination (FAD).

Both of the FAD versions highlight the four-year journey of the Mu.Ta.Lig COST Action CA15135 as well as the main outputs achieved, including publications on peer-reviewed articles, scientific contributions held during the Annual Meetings, the Working Group (WG) Meetings and the Training Schools. Further documentation and the goals achieved are also exposed through the WG leader’s interview.

Unfortunately, the COVID emergency created some problems and has delayed the production of the planned FAD multimedia product, but it didn’t prevent the release exactly on the day expected (April 21st 2020).

Both the two YouTube versions of the FAD video are accessible through the official website www.mutalig.eu or directly to the following links:

Short version (about 4 min)

Full video  (about 18 min)

The capacity of the Net4Science spinoff to valorize the consistent scientific efforts done in this four-year extraordinary journey is demonstrated in this multimedia product and can be considered an added value of this innovative SME.

Net4Science is fully involved in the ENTRAP-Cov IMI2 call 21 EU proposal against the SARS-CoV-2 virus

The Innovative Medicines Initiative (IMI) is the Europe’s largest public-private partnership in the Life Sciences. Its aim is to speed up the development of better and safer medicines for patients, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration among universities, research centers, pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organizations, and medicines regulators. Through the IMI2 programme, the budget for the period 2014-2020 is €3.3 billion. Since the SARS-CoV-2 outbreak exploded, also IMI has promptly made significant resources available on the IMI2 Call 21 in order to provide novel diagnostic and therapeutic tools against SARS-CoV-2 virus. Several research groups have worked to apply credible and potentially fundable proposals.

At the University “Magna Græcia” of Catanzaro, the Medicinal Chemistry group, by means of the academic spinoff Net4Science, in collaboration with the Infectivology group of the Department of Medical and Surgery Sciences, have been involved in a new consortium consisting of more than 25 partners dedicated to dealing with the coronavirus emergency with all the available scientific resources.
The project leader is the Virology team of the University of Rome “Tor Vergata”, through the scientific proposal entitled “Evolutionary Novel Approaches for a Therapeutic Response Against Pan Coronaviruses (ENTRAP-Covs)” submitted to the IMI2 Call 21 “Development of therapeutics and diagnostics combatting coronavirus infections”. The proposal puts together prominent Italian partners and others located in various parts of Europe (France, Belgium, Germany, Holland, Hungary, United Kingdom). The network includes universities (Rome Tor Vergata, Catanzaro, Milan, Palermo, Rega Institute KU Leuven, Hamburg, Hannover, Liverpool), institutions and foundations (Istituto Nazionale Malattie Infettive “Lazzaro Spallanzani”, Ospedale Pediatrico Bambino Gesù of Rome, INSERM of Paris, Fondazione Aviralia, Telethon), SMEs and big pharma companies (Net4Science srl academic spinoff, Chemical and Pharmaceutical Innovation TANK, Pharmacoidea Ltd, Good Clinical Practice Alliance – Europe, Artemis Bio-Support, MiDiagnostics, First Health Pharmaceuticals, Takis, Menarini Ricerche, Menarini Biotech, Zambon, Astra Zeneca, Merck Sharp & Dohme, Diasorin).

The ENTRAP-Covs consortium aims at the following objectives:
1. Repurposing and drug discovery against SARS-CoV-2.
2. Fast early diagnostics.
3. Biomarker identification by analyzing both viral and host factors responsible for SARS-CoV-2 pathogenesis.

The partner networking, articulated through specific work packages, will be able to provide innovative diagnostic and therapeutic tools to fight the SARS-CoV-2 outbreak, will contribute to the internationalization levels of the University’s research in Europe and will consolidate the performances and competitiveness of the involved companies.

The project was submitted on March 31st 2020 and is currently under evaluation.

Net4Science has submitted its first patent request for innovative multi-target anticancer agents

Technological transfer is one of the major issues of the young academic spinoff Net4Science. During its first year of activity, a consistent work was carried out by our scientists with the aim to develop novel multi-target small molecules against neoplastic diseases. A family of novel heterocycle compounds, were characterized and tested on preliminary models of hematological cancers. The inhibition properties and the multiple mechanism of action profile them as promising therapeutic tools, especially against lymphoma and leukemia.

Net4Science provided also with full application of this invention directly submitting it a European level. It includes the synthetic procedure to prepare the proposed series of novel inhibitors, their full chemical characterization, in vitro early toxicity and off-target liability assays, best candidate IC50 values for a set of them against six lymphoma cell lines.

The patent has been submitted on January 2020 and in few months will be available. Any request about it can be done contacting us by email or phone.